The Importance of Countering Biosimilar Disparagement and Misinformation.

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Hillel P Cohen, Dorothy McCabe

Abstract

Biosimilar use is limited in some healthcare systems because biosimilars are not well understood by many healthcare professionals and patients. The knowledge gap is exacerbated by disparagement of biosimilars and dissemination of misinformation, whether intentional or otherwise. There are several different types of disparagement and misinformation directed towards biosimilars as a class, including statements about biosimilar science or policy that are factually incorrect; misleading information, where the information is correct, but is provided out of context; incomplete information, where only partial or a limited set of facts are provided; creation of a false narrative, especially in scientific and medical literature, that provides a set of references to support incorrect conclusions; and negative message framing of factual statements to create a negative perception. Disparagement and misinformation about biosimilars can be countered by educational efforts, appropriate oversight, and regulatory activities with the option of enforcement action by governmental agencies, if warranted. Balanced educational materials about biosimilars should be made easily accessible. Physicians, nurses, pharmacists, and patient advocacy groups sh...Continue Reading

References

Oct 25, 2012·Blood·Martina WeiseChristian K Schneider
Apr 9, 2013·Nature Biotechnology
Nov 1, 2016·Advances in Therapy·Hillel CohenJonathan Uy
Jan 21, 2017·Journal of Medical Internet Research·Sharon Swee-Lin Tan, Nadee Goonawardene
Jul 12, 2017·Journal of the American Pharmacists Association : JAPhA·Judy Crespi-Lofton, Jann B Skelton
Sep 6, 2017·Current Medical Research and Opinion·Allan GibofskyDavid T Rubin
Dec 30, 2017·Expert Opinion on Biological Therapy·William C LamannaMartin Schiestl
Jan 19, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ross A McKinnonJohannes B Prins
Feb 8, 2018·Arthritis & Rheumatology·S Louis BridgesUNKNOWN American College of Rheumatology
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanRichard L Schilsky
Apr 13, 2018·ESMO Open·Andriy Krendyukov, Martin Schiestl
Sep 10, 2018·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Laura E RaffalsDavid T Rubin
Oct 1, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lars Erik KristensenArnold G Vulto
Nov 22, 2018·Clinical Pharmacology and Therapeutics·Niels S VermeerAna Hidalgo-Simon
Apr 2, 2019·Alimentary Pharmacology & Therapeutics·Lieven PouillonLaurent Peyrin-Biroulet
Apr 26, 2019·Therapeutic Advances in Gastroenterology·Ágnes MilassinTamás Molnár
Dec 4, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Binita DuttaSteven Simoens
Dec 17, 2019·United European Gastroenterology Journal·Laurent Peyrin-BirouletSilvio Danese
Dec 25, 2019·Nature Reviews. Rheumatology·Jonathan Kay
Sep 10, 2020·Journal of the Canadian Association of Gastroenterology·Blake Murdoch, Timothy Caulfield
Sep 10, 2020·Journal of the Canadian Association of Gastroenterology·Gilaad G KaplanRemo Panaccione

❮ Previous
Next ❯

Citations

Nov 4, 2020·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Liese BarbierIsabelle Huys
Feb 10, 2021·Pharmaceuticals·Yannick VandenplasIsabelle Huys
Feb 10, 2021·Research in Social & Administrative Pharmacy : RSAP·Simani M PriceKathryn J Aikin
Apr 4, 2021·Pharmaceuticals·Félix Lobo, Isabel Río-Álvarez
Apr 8, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Allison R KolbeAmber Jessup
Aug 23, 2021·Pharmaceutical Medicine·Sonia Tadjalli Oskouei, Andrew R Kusmierczyk
Nov 3, 2021·Drugs·Liese Barbier, Arnold G Vulto

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Lupus
Christopher J Edwards, Salvatore Bellinvia
Journal of Drugs in Dermatology : JDD
Jerry Bagel
Journal of the European Academy of Dermatology and Venereology : JEADV
J Barker
Connecticut Medicine
Adam Ross, Kelly Richard
JAMA Oncology
Sandeep Parsad, Chadi Nabhan
© 2021 Meta ULC. All rights reserved